To study the time course of drug effects in biological systems requires appreciation of drug disposition within the organism; the science of pharmacokinetics. We need also to appreciate how drug effects relate to their concentration in plasma and at the site of action; this is pharmacodynamics. For the specialty of anaesthesia, these two related disciplines have made it possible to understand how anaesthetic drugs can have rapid, profound effects which dissipate rapidly and predictably. Typically, in pharmacokinetics and pharmacodynamics, an empirical mathematical model is defined that describes drug effect time course after administration. That model can then be used mechanistically to predict the action of other doses. Thus, doses and treatment regimens can be manipulated to optimize the safe and effective use of drugs. This is the true use of pharmacokinetics and pharmacodynamics; determination of appropriate dosing regimens.
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If the mechanistic extrapolation of an empirical pharmacokinetic model developed from data collected in a subject or subjects is reasonable, then we can attempt to predict what will happen in a further subject. In truth, the next subject often does not match our prediction. Of course, we do not expect that all patients respond in a similar manner; there is something missing from the model, a factor to account for variation between patients. Intuitively, we also expect that predictions are more in error the more different is the patient from those that were studied originally (e.g. extreme age or disrupted physiology). 6 If we can model the variability between patients, we can predict the magnitude of the expected discrepancy between our predictions and the observations in the next subject. Further, if we can model variability which can be explained on the basis of physiological differences, then predictions are improved because the unexplained residual variation is reduced. As doctors, we treat patients who are sick and it is these patients who are most likely to have drug effects inconsistent with our predictions. Conventional pharmacokinetic models take little account of physiological or pathological variation, and fail to predict the changes in drug effects which would be of greatest interest. They fail to take account of the complexity of variation within the populations in whom the drugs are used and make (Br. J. Anaesth. 1998; 80: 488-501) Keywords : pharmacokinetics, models; model, pharmacokinetic only rudimentary attempts to explain or predict these variations. For the anaesthetist using drugs in the entire population, young and elderly, sick and healthy, the variability in the pharmacokinetic parameters and how this variation is predicted by physiological variables is more useful then knowledge of the precise structure of a pharmacokinetic model.
Population approaches to pharmacokineticpharmacodynamic modelling attempt to integrate the variability of the parameters of the pharmacokinetic model into the modelling process and provide tools to explain these variations on the basis of differing biological characteristics. Some population approaches are capable of quantifying determinants of drug concentration or effect in individual patients, but it is the integration into the modelling process of variability in the structural parameters between patients that differentiate population methods from other methods. This integration alters profoundly the nature and quantity of information that is required from each individual. Typically, with a population approach, the entire population studied is modelled together and there is no necessity to have sufficient information data from each individual to independently define a predictive model for that individual. Small amounts of data collected in a non-stringent manner from large populations of patients can be modelled successfully. Thus population pharmacokinetics provides a tool allowing us to learn more effectively what we need to know to administer drugs safely in the clinical environment; namely, the degree and source of variation in the determinants of drug action in the population.
Sample mean pharmacokinetic parameters of a group of individuals provide a crude "typical" population model but erroneous estimates of variability. While this might be considered a form of population method, for the purpose of this article this methodology will be called the traditional two-stage method. Only methods which attempt to improve on traditional two-stage estimates of both "typical" parameters and variability in those parameters will be called population methods.
the population. With traditional approaches, a model is defined for each individual, the parameters of which describe the plasma concentration (or effect) over time; these individual structural parameters are then treated as variables and are summarized across individuals using statistical parameters (typically sample mean and sample standard deviation). This approach, while satisfactory under some circumstances, is flawed. To understand why, it is necessary to consider in considerable depth the nature of pharmacokinetic data and, in particular, to understand the differences between measured variables and descriptive parameters, and precise measurements and imprecise estimates. The traditional approach to the analysis of pharmacokinetic data gives less information than might be extracted from the available data because it treats imprecise estimated parameters as precise measured variables. Ultimately this prevents the development of more sophisticated models.
MEASUREMENTS, VARIABLES AND PARAMETERS
Biological variables (as the name implies) demonstrate variability between and within individuals. To fully characterize a biological variable within an individual or a population requires a measure of this variation and a measure of the typical magnitude of the variable itself. The measures used to perform these functions are statistical parameters (often the standard deviation and the mean). Frequently, the variable can be measured (with a defined degree of precision) but, because we cannot take every measurement or study every subject, the parameters (e.g. mean and standard deviation) that characterize that variable can only be estimated (the estimates are correctly termed the sample mean and sample standard deviation). If we take arterial pressure as an example of a variable that we might measure with a great deal of precision, across individuals (or across time in one individual), we create a sample of values; we can take the sample mean and sample standard deviation of this series as estimates of the true mean and true standard deviation (which we can never know). Estimates are different from measurements in their additional degree of imprecision (i.e. they differ from the "true" value by an unknown amount). We acknowledge the additional degree of imprecision which arises from the estimation procedure in the standard error of the estimate (or in the confidence interval). Almost certainly the estimate of the mean that we obtain is not the same as the true mean for the population, indeed it may be quite different.
When the variable which we wish to characterize is itself estimated rather than measured, we have another source of imprecision; the relative importance of the two sources of imprecision may be difficult to separate and may also be important. This is the case in pharmacokinetics. The measurement made (with a small, but more importantly, defined degree of imprecision) is, typically, the plasma concentration of a drug. Plasma concentrations are characterized using descriptive parameters (e.g. clearance) which are estimated (sometimes with considerable imprecision). These estimated structural parameters then become the "variables" which are characterized using statistical parameter estimates (i.e. sample mean and sample standard deviation).
The precision of the estimate for an individual's structural pharmacokinetic parameters can itself be estimated (and expressed as the standard error) and may be quite different between two different individuals (one may have more or better quality data). With the traditional approach, when we characterize these parameters for a population (e.g. define the sample mean and sample standard deviation) we have no mechanism for passing on our knowledge of the different precisions for each individual. The imprecision resulting from estimation of the sample mean and sample standard deviation of the pharmacokinetic parameters is compounded by the (perhaps considerable) imprecision already present in the pharmacokinetic parameter estimations for each individual. These two sources of imprecision cannot subsequently be separated, and are interpreted as variation between subjects. Put succinctly, the two-stage procedure for the characterization of pharmacokinetic parameters in a population confounds the precision error in the estimation of an individual's structural pharmacokinetic parameters with the variability in those parameters between individuals.
Imprecision in the estimation of pharmacokinetic parameters for an individual may be greater than we might intuitively expect. This is because of covariance in the pharmacokinetic parameters. Taking a simple monoexponential decline, two parameters are necessary to describe such a pattern, one to describe the rate of decline and one to scale the initial concentration. In the many possible combinations of the two parameters which describe a decline similar to one observed, the two values are not independent, indeed they are highly interdependent. Consider the following experiment: on 10 separate occasions an identical dose of drug is administered to the same individual. On each occasion, plasma concentration data are obtained at identical times. Even if the underlying pharmacokinetic model is identical, we do not expect identical sets of plasma concentration data because each time the plasma concentration is measured there is a small error. When models are fitted to data thus obtained, a slightly different set of structural parameters emerges on each occasion. The data in figure 1 represent the results of simulating such an experiment. The underlying model has one compartment and data were simulated 10 times with random error coded into each plasma concentration. Onecompartment models were then fitted to the data set by set, producing 10 sets of pharmacokinetic parameters. There is apparent variation in the estimations of volume of distribution and clearance, yet we know that the true parameter values of the underlying model were identical for each set of data. The apparent variability between administrations is actually a manifestation of imprecision in each parameter introduced by the estimation process. The variation seen in each parameter is mirrored by highly correlated variation in the other. Thus considerable imprecision in both parameters is consistent with relatively little variability in the predicted plasma concentration. If the 10 drug administrations had been to different individuals and the traditional approach to analysis had been used, the imprecision in estimation of, and covariation in, the estimated pharmacokinetic parameters would appear as inter-individual variability in the pharmacokinetic parameters. Consequently, the investigator concludes (erroneously) that there is more variation in the pharmacokinetic parameters across the population than is really the case.
ESTIMATION AND WEIGHTING
We have examined the differences between measured variables and estimated parameters, and the problems that arise when we nest two estimation procedures, with statistical parameters (e.g. sample means) being estimated for structural pharmacokinetic parameters (e.g. clearance) which have themselves been estimated. Now we will examine the problems associated with estimation of structural descriptive parameters in more detail.
For a parameter describing the behaviour of a variable within a population of values (e.g. mean arterial pressure of a series of measurements) each individual measurement must by definition contribute some information. In the case of a sample mean this is an equal amount from each value for the variable. Implicitly we assume that each value is equally free of error and all values should be given equal weight in the determination of the parameter. If we examine our data before calculating a mean and notice that one value is unusually different from the rest, then we might exclude it as it is more likely to be in error. This is an example of weighting, where the unusual value has been down-weighted to contribute less information because it is more likely to be in error; in this case it is given zero weight.
In the same way when we describe a decline in plasma drug concentration (or change in drug effect) over time using a structural model, each value for drug concentration or effect contributes a certain amount of information to the estimate of the parameters. However, in this case the variable measured is not on the same scale as the parameter. The value to which the measured variable is approximating is the expected plasma concentration (the prediction). The prediction is analogous to the sample mean of the series of arterial pressures; each arterial pressure measured approximates the sample mean arterial pressure which predicts the true average arterial pressure. Unlike the sample mean arterial pressure (which has just one value in the same order of magnitude as the measurement) the predicted plasma concentration has many values. It is a function of the structural parameter and time and has many values which may span many orders of magnitude. Appropriate weighting of the observed values becomes a complex task. 52 Estimating structural parameters which define a model describing a set of data always involves some variation of a least squares procedure (minimizing the sum of the squares of the difference between observed and expected values). The simple least squares procedure often will suffice but is known to produce biased parameter estimates with pharmacokinetic data. One reason for this is that plasma concentrations often decline in a polyexponential manner over time; they usually span many orders of magnitude. We expect the error of measurement to be larger for greater values. If we wish each value to contribute an equal amount of information to the final parameter estimation (a not unreasonable starting point) we must take account of the size of the expected error as a proportion of the size of the prediction, or larger values will contribute too much information. In addition, if visual inspection of the data indicates that a value is outside of what we would expect considering the rest of the data, then we might wish to reduce its influence (as we did with the outlier when calculating mean arterial pressure). We might down-weight it as a function of how far it lies from the expected value based on our knowledge of the other data points. The technical details of more sophisticated variations of ordinary least squares (e.g. extended least squares) are beyond the scope of this article; suffice to say that they can weight data optimally. 51 67 68 To weight appropriately requires that we make some assumptions regarding the distribution of the errors around the expected value of the observation 34 -this is what the sophisticated variations of least squares estimation permit. The most unbiased estimates are produced by procedures that allow the data to contribute to the assumptions made about the distribution of the errors. The more data there are, the better these assumptions are, and the more precise are the parameter estimations.
Practical advantages of the population approach
We have considered the problems that arise with an uncritical approach to pharmacokinetic analysis. If we simply fit each individual and then calculate sample mean pharmacokinetic parameters, we have no valid mechanism for weighting data from well conducted or problematical studies, or for weighting the parameters which come from studies with just a few or many data points. We also tend to conclude that there is more variability in the pharmacokinetic parameters across the population than is truly intrinsic to the data. As some of this apparent variability is consequent from imprecision in the individual parameter estimates or from covariation in those estimates within an individual, we draw erroneous conclusions as to the source and nature of any explanation for this variation. Probably because we are aware of these limitations, we confine pharmacokinetic analysis to well designed, well conducted stud- ies so that the consequent misinformation is limited. Assume that there is an estimation method available which can fit data taking account appropriately of how "good" each data point is both within the data for that individual and weighting that individual's contribution according to how much information there is about him. Then we can perform pharmacokinetic, or pharmacodynamic, or indeed many other types of data modelling using data collected in very non-stringent ways.
With a finite resource available for the conduct of a pharmacokinetic study, we have a dichotomy of choice regarding the number of subjects that we study. We might study a few individuals and collect a great many blood samples from each individual, or we might study a great many patients but collect only a few samples from each one. Under the constraints of the traditional approach to pharmacokinetic analysis only the first approach is viable, and if the data are truly extensive within each individual then structural parameters may be estimated with precision and many of the problems previously identified are minimized. Both approaches have a place, but the second approach (only possible with population pharmacokinetic analysis), even assuming valid estimation procedures, gives superior information on the degree of variation and any explanation for this variation across the population. This is exactly the type of information that we defined as being valuable to the clinician. Further, if the method of analysis can weight data appropriately, perhaps we can model data collected not as part of a study but randomly collected in a very sparse manner in the course of treatment. Thus the population approach to pharmacokinetic analysis provides not only a tool to analyse pharmacokinetic data correctly, it can also facilitate experimental designs that are better able to yield the type of information that is useful.
Methods of population pharmacokinetic modelling
To understand the validity, advantages and disadvantages of the various methods for population modelling, we must first define some concepts for the structural and statistical parameters that make up the model, and the notation for these.
NOTATION
The following notations have become commonplace in the literature of population modelling.
Factors which predict response are notated as x and observed responses are notated as y. Individuals are known as a number I and the number of individuals studied is k (such that each individual is numbered so that i:1, i:2, …i:k). Similarly observations within an individual are known as a number j and the number of observations within an individual is ni (such that each observation is numbered so that j:1, j:2, …j:ni). With these notations we can consider the mathematical treatment of both individual models and population models. Below we will consider two types of models: structural models describe only a shape or curve (with no information on the distribution of random variation), and data models describe not only an underlying shape or curve, but also the nature of the distribution of the random variation expected (or observed) in the data.
Traditional structural model
Traditional structural modelling is applied to each individual's data in turn. The parameters emerging from this process apply only to that individual. The model may make no assumptions on the expected distribution of the residual errors about the predicted value for y. Put in terms of our notation the data take the form:
where y j :the jth observation of y in this individual; f(, x):parameterized curve describing an expected value for the response as a function of x for a parameter value -it is the predicted value of the response for this individual; and :parameter vector identifying the form of the relationship between x and y for this individual.
The values of any in the equation are altered so as to minimize the sum of the differences between the two sides of the equation for all values of y j and hence the pharmacokinetic parameters are determined. The model recognizes only one individual at a time.
With this model there is no opportunity to weight the influence of a data point according to the expected distribution of the residual errors. An additional factor is required to transform this traditional model from a purely structural model for an individual to a data model for an individual, that is a statistical component describing the nature of the distribution of the random residual errors that can be used to define an expected degree of error for any particular prediction.
Individual data model
The corresponding data model for an individual has both structural and error distribution information. Put in terms of the described notation the data take the form:
where y j :the jth observation of y in this individual; f(, x j ):parameterized curve describing an expected value for the response predicted by the value of x at the jth observation in this individual modified by the vector of the parameter ; :parameter vector identifying the form of the relationship between x and y for this individual; and ε j :zero-mean measurement error. Within this individual, all values of ε j (ε 1 … ε n ) come from a series which is normally distributed and has a mean of zero. How the variance of the epsilon varies with the magnitude of the expected observation may be coded into the modelling process. It might be assumed to be constant for all observations or it might be related to the size of the expected observation. The influence of data points can be weighted according to how far they lie from the expected value measured against this distribution. The additional factor or factors which transform the structural model to a data model are ε variables. Epsilon (ε) has a new value for each observation but within an individual has a mean of zero and the values are normally distributed. The variance of epsilon is denoted by 2 (sigma squared) and the standard deviation by . The values of any are estimated as parameters of the model when they are fitted to the data. Thus the probability of any particular value of epsilon can be determined, and the appropriate weight of each observation assigned as part of the estimation process of the model.
Population data model
The corresponding data model for a population of individuals has both structural and error distribution information, and in addition it has information about the distribution of i between the individuals in the model. Put in terms of the described notation the data take the form:
where y ij : the jth observation of y in the ith individual; f(( + i ), x ij ) : parameterized curve describing an expected value for the response predicted by the value of x at the jth observation in the ith individual modified by the vector of the parameter , itself modified by the factor i ; :parameter vector identifying the form of the relationship between x and y for the typical individual; i :zero-mean variation in . The entire population has just one value for each structural parameter . Each individual's value for the structural parameter ( i ) is determined by modifying by i . The population of values for (one for each individual) has zero mean and is normally distributed. How the variance of the values of varies according to the magnitude of the has to be assumed and coded; ε ij :zero-mean measurement error. Within the ith individual, the value of ε j is random, normally distributed and has a mean of zero. How the variance of epsilon varies with the magnitude of the expected observation must be assumed and coded into the modelling process. It might be assumed to be constant for all observations or it might be related to the size of the expected observation. The additional factors in the population data model over the individual data model are the factors. An variable has a new value for each individual subject included in the data, but within a population has a mean of zero and the values are normally distributed. The variance of is denoted by 2 (omega squared) and the standard deviation by . The value of any is determined as a parameter of the model.
Thus a population data model for a data set (assuming that there is more than one observation per individual and more than one individual) can be defined with the use of three types of parameters. Theta () parameters are constant throughout the population, and consequently have just one value. Normally they are used as structural parameters of the model and their estimated values serve to define the structural model for a typical individual. They are also used to model for non-random variability between subjects (i.e. variation that can be explained, for example clearance is, on average, 30 % less in one gender compared with the other). Eta () variables (the parameter in the model is their variance 2 ) have a new value for each individual but values are constant within an individual subject (or set of data intended to be treated as coming from one subject). They are constrained to have zero-mean and be normally distributed within a population. Typically they are used to code the random variability of structural parameters between individuals. Finally, epsilon (ε) variables (the parameter in the model is their variance 2 ) assume a new value for each observation, they are constrained to have zero mean and be normally distributed.
It does not follow that each must have a corresponding (e.g. in a one-compartment model we might assume variability in clearance but not volume). Nor does it follow that there is only one parameter in a population model (e.g. we might assume that the variance of the expected measurement errors is mostly proportional to the magnitude of the expected error, but at low values becomes larger than this would predict, and this would require two parameters).
STATISTICAL METHODS
Many statistical methods have been propounded for estimation of population pharmacokinetic parameters and these are summarized below and in table 1. Whatever method is used many assumptions underlie the estimation process. Much care is required in the selection of models and parameterizations. 2 37 44 Naive pooled data approach If we focus attention entirely on the pharmacokinetic parameters which characterize the structural model and ignore completely the variance in these parameters when they are determined separately for each individual, then it might seem appropriate to pool all the data together as if they came from a single individual. 61 Such an approach is flawed in several respects as it ignores the dichotomy of source of variability in the response variable (plasma concentration). By the nature of the assumptions underlying the approach no information is available on individual profiles or parameters. Although standard errors can be calculated for the structural parameters estimated, measures of variability between individuals cannot be determined. Aspects of the pattern of the response which emerge from variation between individuals might easily but erroneously be interpreted as a more complex structural model than can be observed for any individual. Although the approach may be satisfactory when data are extensive for each individual and there is relatively minor interindividual variability, 35 deviations from such conditions may result in erroneous results. 28 32 The approach is not recommended. 61 
Two-stage approaches
The traditional approach to pharmacokinetic analysis is to analyse subjects one by one, estimating parameters for each. Subsequently, the parameters describing each individual are combined in a summary measure (usually the arithmetic mean, but perhaps a geometric or weighted mean (e.g. weighted) according to the uncertainty associated with individual parameter estimates). The problems associated with this approach have been described previously.
In a population analysis, information on the structure of all individuals can input into the estimation of each individual's parameter estimates to "improve" these estimates. This is clearly not possible with a traditional two-stage approach, but some elaborations of this method attempt to implement this. 75 These include the "general two-stage" and "iterative two-stage" 53 procedures. They consist of multiple iterations through an algorithm, each iteration allowing all individuals' parameter estimates to modify the estimates for each individual. The details of these procedures are beyond the scope of this article, but until recently were suggested as being more reasonable than the next approach (non-linear mixed effects modelling) because of the latter's high computational overhead. 53 Even these procedures do not dispense with the necessity to obtain sufficient data from each individual so that their structural parameter values may be estimated. The same restrictions apply to the Bayes approach. With the Bayes approach, some prior but vague assumptions are made regarding the form of the mean population parameters and variability, and then information from each individual is used iteratively to adjust the assumptions. The Bayes approach has the advantage that it weights the contribution of each individual to the estimation of population structural parameters appropriately according to the amount of information available for each.
Non-linear mixed effects modelling
This is a procedure introduced by Sheiner and Beal in 1979. 69 The acronym NONMEM has become a common way to refer to this method, but it also refers to a proprietary computer package provided by a group headed by the same two individuals. The computer program NONMEM is not the only one now available for this type of analysis. The technicalities of the NONMEM approach are beyond the scope of this article 5 ; essentially NONMEM is a full implementation of the population data model described above. All data from all individuals are fit together with information about the identity of individuals. Assumptions must be made regarding the form of the variation in each parameter between individuals and regarding the distribution of measurement errors. The form of each individual's concentration (or effect) profile is assumed to be similar to the "population" profile. Individual parameter values for some (not necessarily all) of the structural parameters are assumed to vary around the mean "population value" by a normal (or function of normal) fashion. Individual observations are assumed to vary around the predicted value in a normal (or function of normal) fashion and the values of the , and are estimated.
The NONMEM approach uses extended least squares in its minimization algorithm and weights values and individuals appropriately. It can provide valid structural parameter estimates for a "typical" individual on as little as two or three data points per individual. It has the advantage, when combined with empirical Bayes forecasting, of not requiring sufficient data from each individual to estimate their structural parameters independently. 26 48 77 It also has the advantage that a full variance-covariance matrix for all parameter estimations is estimated. Consequently the precision (standard error, or confidence interval) of each parameter estimation can be determined. The "true" variability of each structural parameter across the population is provided, 20 unconfounded by variation arising from assay error within an individual.
The main disadvantage of the method arises from the computational complexities involved in the estimation process. These are essentially two-fold. First, many assumptions must be made about the form of the structural model and the form of inter-individual variation between parameters. If the model is poorly or excessively parameterized (for instance attempting to fit a three-compartment model to data that truly support only two compartments), the method may frequently run into numerical difficulties. Second is the "overhead" of computational time required for the method. Even relatively modest problems may take hours of computation for a single estimation, and when data are extensive within each individual then it is not uncommon for a single estimation to take several days. As computers become faster and more powerful this is becoming less of a consideration. For many problems the nonlinear mixed effects approach provides superior solutions compared with the two other approaches. [64] [65] [66] Non 62 63 These individual estimates for structural parameters can then be used to guide the determination of any "explainable" variation. 22 44 Thus individual values for clearance, for example, may be plotted against a physiological covariate (e.g. weight) to gain a graphical insight into whether clearance varies systematically with weight.
What has the population approach told us about anaesthetic drugs?
Although appropriate methods of dealing statistically with pharmacokinetic and pharmacodynamic data have been available for about two decades they have only slowly reached acceptance and widespread use. No doubt this was in part a function of the computationally intense nature of the required analyses, which kept these techniques as a specialist tool for much of that time. It is only in the 1990s that population pharmacokinetic analysis has appeared more than sporadically in the methodology of studies of anaesthesia drugs and techniques. The review which follows concentrates on studies which use full data models to explain drug time course in entire populations; and on studies which examine the utility of such models. Studies of anaesthetic drugs and techniques which use mixed effects modelling or naive pooled data analysis are also summarized in table 2.
OPIOID DRUGS
Probably because of the difficulty in monitoring their effects, opioid drugs have received much attention from population pharmacokineticists. The effect of an anaesthetic or neuromuscular blocking agent can be observed during an operation using simple, widely available methods. However, there is no simple test to monitor the effects of opioids in anaesthetized patients. Inadequate dosing may result in intraoperative stress or postoperative pain while an overdose may compromise respiration. A predictive model may allow these undesirable outcomes to be avoided more frequently. By its very nature, mixed effects modelling is well suited to predictive (mechanistic) modelling as its "typical" parameter set is not necessarily a geometric mean of individual parameters but is probably more representative of a typical individual. In addition, a variance-covariance matrix is estimated and allows individualization of parameters via Bayesian forecasting. In predictive modelling, variability in the model parameters can often be reduced by modelling parameters as functions of physiological covariates (e.g. gender or weight), hence improving the accuracy of the prediction for each individual. A difficulty arises because of the number of possible candidate parameters and covariates to test in fresh models, especially given the computational overhead of mixed effects modelling. Some general schemes to ensure a systematic approach and thereby minimize the resources committed to each problem have been proposed. 44 
Alfentanil
Of all of the anaesthetic drugs, alfentanil was the first to receive the intense scrutiny of population pharmacokinetic methods. Using a randomly selected subset representing half of the plasma concentration data points from four studies, 7 11 29 57 Maitre and colleagues built a population pharmacokinetic model using non-linear mixed effects modelling. 43 The article was accompanied by an editorial 27 and may represent the first mainstream introduction of population methods into anaesthesia research. The group investigated the influence of several physiological covariates on the structural parameters of the model in an attempt to explain some of the inter-individual variability in the parameters of a three-compartment model. They noted that differences between patients in observed drug disposition could be explained by allowing variability in just two structural parameters (clearance and central volume of distribution). Had they had more data they might have been able to define degrees of variability in more of the pharmacokinetic parameters. The authors were able to explain some of the variability observed on the basis of physiological covariates (e.g. they found that clearance was not influenced by age up to 40 yr, then declined in a linear manner). When all explainable variability was modelled, the remaining degree of variability was small (coefficients of variation of 48% and 33% for clearance and central volume of distribution, respectively), and there was a considerable degree of correlation between these parameters. Hence the study illustrates effectively some practical advantages of the population approach. Had the authors used traditional two-stage data analysis they would have had no option but to report variability in all pharmacokinetic parameters, probably at a much greater magnitude than is truly the case. The authors validated their model against plasma concentration data not used in the analysis and produced a confidence range of prediction for plasma concentration in each individual.
There are some limitations to the use of information generated by this analysis (which were acknowledged by the authors). Principle among these is that the model provides only a predicted range of plasma concentrations for an individual (not drug effect which is the variable of true interest). Thus plasma concentrations have no real value unless compared against some prior knowledge of the magnitude of plasma concentration associated with desired effects. Using data from a previous study 3 4 designed to evaluate the range of plasma concentrations of alfentanil associated with clinical effects, the group went on the evaluate the predictive performance of their "typical" population pharmacokinetic model. 39 They found that their model predicted plasma concentrations with a small mean bias (7.9% under prediction) and a mean absolute error of 22%. They considered that these results indicated that their model was sufficiently robust for clinical use.
That further individuals given a dose of drug to achieve a given response will demonstrate a range of responses is intrinsic to any pharmacokinetic model. Thus if the population pharmacokinetic model can be "modified" for an individual, predictions are improved for that individual. The same research group carried out a further study on the same data designed to investigate methods of individualizing the pharmacokinetic model used for dosing. With prior knowledge of the behaviour of the population (both "typical" behaviour and variability), relatively little information is required using empirical Bayesian techniques to estimate the pharmacokinetic parameters of a new individual. 62 Using a single plasma concentration value from each individual the group applied this Bayesian forecasting to produce individualized pharmacokinetic models and demonstrated that the mean absolute error could be reduced to 13.8% using a single plasma concentration from each individual to "modify" the structural model for that individual. 42 analysis. 54 Contrary to expectations, this study found that the model of Scott predicted plasma concentrations in two disparate populations substantially better than Maitre's model (which under predicted plasma concentrations of alfentanil). The authors discussed a variety of explanations for this unexpected finding. Jenstrup and co-workers evaluated the Maitre model in middle-aged females and also found systematic under prediction of plasma alfentanil concentration. 33 Similarly, Barvais and colleagues 55a administered drugs to patients undergoing cardiac surgery according to the Maitre model for the middle aged and the model of Helmers and colleagues 29 (derived using the traditional two-stage approach) for elderly patients. They retrospectively evaluated the predictive performance of these two models and several other alfentanil models taken from the literature. All models under predicted the observed plasma concentrations with the exception of the model of Scott and Stanski. 58 The importance of prospective evaluation of pharmacokinetic models has been acknowledged by the Maitre group. 79 More recently, two further population models of alfentanil have been published. One is derived from data collected in critically ill patients receiving these drugs for sedation in the intensive care unit. 21 In principle, the long duration of drug administration sampled during this study may be advantageous in providing data that allow a very predictive model. However, this model has not been evaluated at present. Interestingly, this model has a clearance for alfentanil which is similar to that of the Maitre model suggesting that it also might under predict alfentanil plasma concentrations in prospective evaluations. Another model, also as yet not evaluated, is derived from data in surgical patients and also has a value for clearance similar to the Maitre model. 17 Alfentanil pharmacokinetics have been investigated in children using naive pooled data analysis. Fiset and colleagues 18 used a model with its parameters estimated using a traditional two-stage approach from data taken from healthy children 25 to calculate infusion doses for 14 further children undergoing cardiopulmonary bypass. The authors used naive pooled data analysis to define new models of varying complexity. The median absolute error of the two-stage model used to compute the dose schedule was 33% but was in the range 18-20% for the naive pooled data models. However, given that these models were estimated from the same data as they were evaluated against, we cannot infer that the naive pooled data method is preferred over the two-stage method. In these studies, very extensive data were available for all individuals so that most pharmacokinetic methods would be expected to perform well.
Remifentanil
Remifentanil is an opioid drug which, because of its disposition in the body, is much more predictable than all other opioids. It is cleared very rapidly so that recovery takes place soon after infusion is discontinued, irrespective of the dose or duration. In this case we desire a pharmacokinetic model more for explanatory than predictive purposes, and population pharmacokinetics has less to offer. Nevertheless, population pharmacokinetic techniques have been used widely in its evaluation, in part because it is a drug which has recently been developed. Two early studies used traditional two-stage and mixed effects modelling to analyse the same data, 16 81 and one of these also used naive pooled data analysis. 16 The data in both of these studies came from small groups of homogenous individuals and consisted of an extensive data set for each individual. Under these circumstances, where the requirements necessary for individual pharmacokinetic analysis are met, and inter-individual variation is expected to be modest, all procedures are expected to perform well. Indeed in both studies all methods gave similar average structural models for remifentanil. The other possible advantage in using mixed effects modelling is its ability to estimate a valid variancecovariance matrix. However, in these particular circumstances, mixed effects modelling gives little advantage because few subjects were studied and variability would inevitably be poorly estimated whatever analysis method is used. Similarly, in a study comparing remifentanil with alfentanil, 17 extensive data were obtained from small groups of individuals; mixed effects modelling was used but probably gave similar results to any other method that might have been chosen. In a study examining differences in response to remifentanil in subjects with liver disease, 12 extensive data were collected from small numbers of subjects and the authors successfully used two-stage pharmacokinetic analysis.
More recently, Minto and colleagues have presented a population pharmacokinetic analysis of remifentanil that depends more critically on the use of mixed effects modelling. 46 This analysis includes extensive data for 65 individuals, some of whom appeared in earlier studies, 16 17 and goes further than many earlier population pharmacokinetic studies of opioids in that a population pharmacodynamic model of spectral edge frequency was also developed. Individual pharmacokinetic analysis was carried out on all 65 subjects, a two-compartment model could be fitted to half of the subjects; the remainder required a three-compartment model. The authors wished to build a covariate model to explain as much inter-individual variation as possible; this is difficult if the structure of the pharmacokinetic model differs between individuals. It is likely that the individuals in whom the data could support only a twocompartment model would have supported a threecompartment model had more or better quality data been available. In this setting, mixed effects modelling of a three-compartment model to all data combined with Bayesian prediction of individual parameter values makes this process possible. Among a host of covariate effects the authors demonstrated convincingly that clearance, central volume of distribution and biophase equilibration all decrease substantially with age while tissue sensitivity to remifentanil increases with age. In an accompanying article, the authors used their model to determine, given the intrinsic predictability of remifentanil, whether any covariate effects that they were able to model would have a clinical impact. 47 
Other opioids
Most available opioids were already well established in clinical practice before population pharmacoki-netic methods began permeating the anaesthesia research community. Consequently there are only sporadic studies of other opioids which use these techniques. Shafer and colleagues 59 used two pharmacokinetic parameter sets 45 58 to program a syringe controller and gave fentanyl to 21 adult patients using one or other of the sets, aiming to produce rapidly stable plasma concentrations. They collected multiple plasma concentrations from each of the patients and analysed these to estimate a new pharmacokinetic parameter set. To achieve this, they first attempted a two-stage approach, but had difficulty because the duration of infusion influenced the parameter estimates to a great extent because of the differing quantity of data. They recognized this problem and used naive pooled data analysis (which would now be recognized as an imperfect solution because it does not weight the input of the individual's contribution to the fit according to the quality of their data). The ability of their parameter set to predict fentanyl concentrations of four previous studies 31 45 58 78 varied from slightly worse to better than the parameters derived by the original investigators using two-stage analysis. Their methodology was rather less naive when they performed a similar study in children and developed a new pharmacokinetic parameter set in children using mixed effects modelling which included a considerable number of covariate effects. 24 Demonstration of linearity (i.e. independence of concentration) in the pharmacokinetics of a drug is of great importance if models are to be used in determining doses and predicting concentrations. This represents a potentially difficult problem in pharmacokinetic research as giving a larger dose typically results in a longer duration of detectable plasma concentration. There may be more information available after the greater dose, and later, slower half-lives may be detectable. Thus a drug which truly has linear pharmacokinetics may appear to be non-linear. Mixed effects modelling is potentially a solution to this problem. Gepts and colleagues have performed such an analysis with sufentanil. They administered multiple dose levels to surgical patients and subsequently analysed plasma sufentanil data using naive pooled, two-stage, and mixed effects modelling. 23 Analysis of linearity was confined to a very sophisticated two-stage analysis however, and although mixed effects and naive pooled models are presented they did not include data from smaller doses, these having been deleted as potentially misleading. The authors conclude that the "best" model emerged from the two-stage analysis. However, if all of the data had been included for all of the analyses, the mixed effects model might have emerged as 'best' as it is theoretically capable of dealing appropriately with censored data from some subjects.
NEUROMUSCULAR BLOCKING DRUGS
As with opioid drugs, neuromuscular blocking agents have been subject to population pharmacokinetic analysis only in recent years: consequently there is a predominance of literature concerning recently developed drugs. A population pharmacokinetic evaluation was coordinated into the clinical development program of cisatracrium. 55 As it models pharmacokinetic and pharmacodynamic data from several hundred patients, it may prove to have considerable predictive value. However, at present it has not been evaluated. A similar project was undertaken during the development of ORG 9487 but has yet to appear in the literature. With neuromuscular blocking agents there has been less emphasis on the predictive performance of parameter sets (perhaps because the effects of neuromuscular blocking agents are easily measured and monitored). Pharmacokinetic modelling can still be useful in explaining differences observed in drug effects between patient groups. When the most likely explanation for an observed difference in effect is determined, the model can be used to predict differences with other dose regimens. Population modelling and mixed effects modelling in particular have a place in providing a sound data model which allows for hypothesis testing. Thus mixed effects modelling can provide a tool to determine the most likely of several candidate explanations for differences between subsets of individual subjects. 44 
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Rocuronium
Four recent studies have used population approaches to determine the explanation for the time course differences of rocuronium in specific subsets of patients. Szenohradszky and colleagues studied 10 healthy surgical patients and 10 patients with end-stage renal failure receiving rocuronium. They used mixed effects modelling to determine which parameters of a three-compartment model varied between groups. They determined that clearance was unaltered by renal failure but that distribution volumes were increased. The authors did not carry out a two-stage analysis which, given the extensive sampling and small numbers of patients, may have given similar results. 76 More recently the same group have reported a similar study comparing healthy patients and those with severe liver disease. 38 They found that clearance of rocuronium was not altered in liver disease but distributional volumes were increased. 38 They went on to use mixed effect modelling techniques to examine the degree to which disposition of rocuronium altered during the course of liver transplantation and found that clearance of rocuronium correlated negatively with duration of warm ischaemia. 19 Larijani and colleagues compared the dose requirements and pharmacokinetics of rocuronium in the presence or absence of isoflurane; parameter differences between the groups were determined using mixed effects modelling. 36 Clearance of rocuronium was increased in the presence of isoflurane, explaining why infusion dose requirements were similar, despite the expected potentiation of rocuronium by isoflurane.
Vuksanaj and Fisher examined the pharmacokinetics of rocuronium in children aged 4-11 yr. 80 To minimize the volume of blood required they sampled each child on four occasions. With such a study design only naive pooled and mixed effects modelling are possible, and individual pharmacokinetics can only be forecast using mixed effects modelling and empirical Bayesian techniques. The authors carried out naive pooled and mixed effects analyses to investigate the influence of covariates on pharmacokinetic parameters. The two techniques gave similar results (i.e. all parameters are best scaled by weight except clearance which is best described by a constant and a constant weight).
Cisatracurium
The development of cisatracurium has included studies analysed using both traditional two-stage pharmacokinetic modeling 8 15 50 and mixed effects modelling. 70 73 Many of the clinical studies conducted during the later stages of the clinical evaluation of cisatracurium involved the collection of a limited number of blood samples from each individual. Such data are suitable for population based pharmacokinetic analyses; two such analyses appear in the published literature. One examines only the effect of age 73 ; the other attempts a general predictive model of concentration and effect. 55 Two studies examined the time course of the effect of cisatracurium and its pharmacokinetics in elderly compared with young adult patients; one used extensive sampling in limited numbers of subjects and traditional two-stage analysis, 50 the other used sparse sampling in a much larger sample of patients and mixed effects modelling. 73 The two studies reported similar "typical" pharmacokinetic model parameters for the two patient groups and concluded similarly that volume of distribution was increased in the elderly. However, the fact that a larger number of patients were studied for the sparse sampling/mixed effects analysis study means that its estimates for inter-individual variability probably are more representative. The mixed effects analysis presents, in addition, a population pharmacodynamic model which is more informative regarding the explanation behind any differences in the time course of the drug in young and elderly patients. More recently, another study has evaluated the infusion pharmacokinetics of cisatracurium (and two other isomers present in atracurium) using mixed effects modelling. 70 Relatively few patients were studied but a negative influence of age on clearance still appeared as a significant covariate effect.
ANAESTHETIC AGENTS
As most anaesthetic agents and sedatives are well established in clinical practice, population pharmacokinetic techniques have been used only sporadically to elucidate residual problems.
Propofol
Recent pharmacokinetic research on propofol has concentrated on children and, not surprisingly, population modelling has been used in these studies. Two groups have studied the pharmacokinetics of propofol in children. 35 49 Both collected extensive samples from limited numbers of children and both determined that in these circumstances naive pooled data analysis, mixed effects modelling and traditional two-stage analysis gave similar results. In the circumstances of extensive sampling and a well conducted study, these findings are expected. Both determined a three-compartment model with clearance and volumes related to weight. If the pharmacokinetics of propofol in neonates are to be determined, a population approach may be necessary.
Frenkel and colleagues have produced a population pharmacokinetic model of propofol from data obtained during long-term infusion in the ITU in 18 patients. 21 Sampling was extensive and in this limited number of patients it is doubtful if a population approach gave any additional information.
Midazolam
Midazolam has a pharmacokinetic profile which makes recovery after its use difficult to predict, particularly in sick patients. 41 Maitre and co-workers developed a population data model of the effects of midazolam from data in 64 subjects. They used Bayesian forecasting to provide individual parameter estimates and used these to guide the modelling of covariate effects. 40 These methodologies have now become routine and are built in to current versions of NONMEM.
Another group has subsequently taken a fresh look at the pharmacokinetics of midazolam in neonates using sparse sampling and mixed effects analysis with covariate effect modelling. 10 Because of the limitations imposed by the small blood volume in neonates, the authors sampled the plasma infrequently; analysis of these data is only possible using population pharmacokinetic techniques. Despite their finding that clearance of midazolam was highly correlated with birth weight and prematurity, even when all covariate effects were modelled, residual variability was still considerable.
Aarons, Mandema and Danhof also examined the problem of predicting midazolam effect from a different perspective. They performed a study in rats and demonstrated that individual pharmacodynamic models (which generally need a priori definition of the plasma concentration) built on a "typical" pharmacokinetic profile have a predictive performance inferior to those built on an individual pharmacokinetic profile. They demonstrated further that an individualized pharmacokinetic model (using just one plasma concentration and Bayesian forecasting to modify the "typical" population profile) was indistinguishable from a full individual model as a base for pharmacodynamic modelling. 1 
Thiopental
Applying pharmacokinetics to explain observed effects with thiopental is fraught with difficulty because of its extremely rapid onset of action. Much of the effect appears very shortly after administration. Compartmental models often make the assumption that drugs mix instantaneously with the volumes into which they are administered. This is not true and this aberrant assumption becomes important when an accurate description is required of the early arterial concentrations of the drug as a base for pharmacodynamic modelling. A group led by Stanski examined the effect of age on the disposition of thiopental using both two-stage techniques and mixed effects modelling. In the first study, 30 using two-stage analysis, they determined that the initial volume of distribution of thiopental is reduced in the elderly and this accounts for the reduced dose requirements in the elderly. In their second study, 74 using mixed effect modelling they were able to include more subjects (who had incomplete arterial concentration data and could not be studied using two-stage analysis) and they excluded patients who had received a bolus (rather than rapid infusion) of thiopental because of the difficulties outlined above. This study preferred a reduced rate of early distribution in the elderly over reduced central volume of distribution as the explanation for the reduced dose requirements. Probably the explanation proposed by the later study for reduced dose requirements in the elderly is more likely given the greater validity of the methods used. In the preceding case, mixed effects modelling was not a prerequisite for the more valid explanation. However, because it allowed inclusion of more subjects, and allowed valid comparison of which parameters were more likely to vary with age, it was instrumental in the discovery process. Of note is the fact that both methodologies correctly identified pharmacokinetic factors as the explanation for reduced thiopental dose requirements in the elderly and both determined that the young and elderly were similar in brain sensitivity and equilibration rate between plasma and brain.
Other anaesthetic agents
Population pharmacokinetic techniques are becoming integrated into the drug development process. Sneyd's group have used mixed effects modelling to characterize the pharmacokinetics and dynamics of a candidate i.v. anaesthetic from data obtained during its first few administrations to volunteers. 71 72 In both these studies extensive plasma concentration data were available from each individual and two-stage analysis would have been possible, but mixed effects modelling demonstrated that the effects of the drug could be explained in each individual with little variation of the model between individuals. As predictability is important in an anaesthetic, this information is useful in deciding if similar compounds are worth studying. Similarly, in two studies, the pharmacokinetics of dexmedetomidine were studied in 10 volunteers 14 and a population model developed to allow inclusion of covariates into the model. 13 The predictive performance of this model was tested on a further six subjects. 13 Both examples represent "pilot" use of population pharmacokinetics as estimates of variability across the population (one of the prime advantages of these techniques) are estimated only with poor precision with such few subjects.
OTHER ANAESTHETIC TECHNIQUES
Mixed effects modelling provides an ability to analyse data collected in a non-stringent observational way. This aspect of population data modelling has been little applied in the anaesthesia literature to date. However, given the ability of mixed effects modelling to explain variation and thereby possibly provide more powerful statistical testing, this may be an important application in the future. Two recent studies in the anaesthesia literature have presented work which takes advantage of this aspect of mixed effects modelling.
Shangraw and Fisher examined the disposition of dichloroacetate (DCA) during liver transplantation. 60 The drug was administered on two occasions by a short infusion and after each infusion, extensive blood samples were obtained. However, because the authors wished to investigate potential changes in DCA associated with removing the diseased liver and transplanting a donor organ, there were three sets of pharmacokinetic parameters, during three phases (paleohepatic, anhepatic and neohepatic) associated with a variable number of samples after two infusions. There would have been insufficient data during some of these phases to fit independent models with acceptable precision. Mixed effects modelling was used successfully by the authors to demonstrate that clearance of DCA approaches zero during the anhepatic phase.
Much of my review has presented population data modelling as a pharmacokinetic modelling technique. The majority of its use has been in pharmacokinetics but population data modelling can be applied to many non-pharmacokinetic data sets. The prerequisites for a population data model are that the data have a structure which can be expressed mathematically; there should be more than one data point per individual; data should be obtained from a variety of individuals; and measurement errors should be expected. Just such an analysis has been carried out recently to model the time course of spinal anaesthesia in a population. 56 Data were collected in a relatively sparse, non-stringent manner for another purpose. After spinal injection, the dermatomal level of spinal block was measured 4-10 times in each of 96 patients. A population data model was fitted to these data and covariate effects sought and modelled. Among the effects modelled (and therefore predicted by the model) was that onset time for block increased with height and decreased with weight. Thus a tall thin person is predicted to have the longest onset time for spinal block and a short heavy person the shortest time. By far the most important aspect of this study is its application of population data modelling techniques to model effect in the absence of drug concentration information (a technique only recently applied to single subjects). 9 Many of the problems currently addressed by clinical research in anaesthesia are potential candidates for this type of analysis.
In this article, I have considered how population pharmacokinetics is concerned with the provision of the most valid possible estimates for the behaviour of drugs in "typical" individuals. As the most obvious purpose for such information is to predict accurately the effect of drugs in new individuals, it is not surprising that tools have been developed to explain variation in drug behaviour on the basis of observable covariates; I have considered these also. I have examined how the methods which have emerged to analyse data addressing these issues have also provided some additional use in allowing valid analysis of observational data. I have examined the value of these methods to anaesthetic research; what informa-tion has been provided that we might otherwise not know. Finally, I have examined how the techniques involved may be used to allow the valid analysis of non-pharmacokinetic complex data sets.
